1.
Br J Haematol
; 204(1): 186-190, 2024 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37833834
RESUMO
Very scarce data exist about outcomes of relapsed multiple myeloma patients who have failed proteasome inhibitor, immunomodulatory drug, anti-CD38 monoclonal antibody and therapies targeting B-cell maturation antigen (BCMA) (Quad-class exposed [QCE]). In this retrospective single-centre study, we determined progression-free survival (PFS) and overall survival (OS) from anti-BCMA failure in 45 QCE patients. Seven (16%) patients received antibody-drug conjugate, 20 (44%) bispecific antibodies and 18 (40%) CAR-T cell. Thirty patients (67%) received ≥1 subsequent line of treatment. PFS was 4.4 months (95% CI = 2.4-12.5) and OS 6.3 months (95% CI = 3.9-14.4). Having an adverse prognosis, QCE myeloma patients remain an unmet medical need.
Assuntos
Anticorpos Biespecíficos , Imunoconjugados , Mieloma Múltiplo , Humanos , Mieloma Múltiplo/tratamento farmacológico , Estudos Retrospectivos , Prognóstico , Anticorpos Biespecíficos/uso terapêutico , Antígeno de Maturação de Linfócitos B , Imunoterapia Adotiva
2.
Haematologica
; 109(1): 357-361, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37470151
3.
Curr Res Transl Med
; 71(2): 103388, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37099834